Journals / Türk Veteriner Cerrahi Dergisi / 2023 / Cilt: 2 Sayı: 1

Thromboelastography evaluation of tissue plasminogen activator therapy in a cat with acute aortic thromboembolism due to hypertrophic cardiomyopathy

Hipertrofik kardiyomiyopatiye bağlı akut aortik tromboembolisi olan bir kedide doku plazminojen aktivatörü tedavisinin tromboelastografi ile değerlendirilmesi

Pages
10–16
Publication Date
2023-10-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, we reported here a successful thrombolysis using tPA and for the first time monitoring the lytic treatment by TEG in a cat with ATE due to hypertrophic cardiomyopathy (HCM).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute arterial thromboembolism (ATE) is a very painful and fatal serious condition in which the thrombus lodges in the trifurcation of the aorta, resulting in death or severe damage to organs if not treated immediately.
📊
Key Findings & Data:Thrombolytic agents such as tissue plasminogen activator (tPA) are preferred as a first choice of the treatment for ATE; however, they should be used carefully because of their possible side effects such as spontaneous bleeding in human and animals.
💡
Conclusion & Impact:Therefore, we reported here a successful thrombolysis using tPA and for the first time monitoring the lytic treatment by TEG in a cat with ATE due to hypertrophic cardiomyopathy (HCM).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akut aortik tromboembolis · tromboelastografi · doku plazminojen aktivatörü

Abstract

Acute arterial thromboembolism (ATE) is a very painful and fatal serious condition in which the thrombus lodges in the trifurcation of the aorta, resulting in death or severe damage to organs if not treated immediately. Thrombolytic agents such as tissue plasminogen activator (tPA) are preferred as a first choice of the treatment for ATE; however, they should be used carefully because of their possible side effects such as spontaneous bleeding in human and animals. Therefore, monitoring coagulation status plays an important role in the management and treatment of dissolving intravascular clots. Thromboelastography (TEG) that measures the dynamics of clot formation, strength, and lysis, and provides information of clot consistency has been accepted as a useful tool for assessing coagulation status and response to thrombolytic therapy. There is no study showing the thromboelastographic monitoring of the thrombolytic therapy with intravenous tPA in cats. Therefore, we reported here a successful thrombolysis using tPA and for the first time monitoring the lytic treatment by TEG in a cat with ATE due to hypertrophic cardiomyopathy (HCM).

Özet

Akut arteriyel tromboembolizm (ATE), trombusun aortun trifürkasyonuna yerleştiği, hemen tedavi edilmezse ölüme veya organlarda ciddi hasara yol açan çok ağrılı ve ölümcül ciddiyetli bir durumdur. ATE tedavisinde ilk seçenek olarak doku plazminojen aktivatörü (tPA) gibi trombolitik ajanlar tercih edilmektedir; ancak insan ve hayvanlarda spontan kanama gibi olası yan etkileri nedeniyle dikkatli kullanılmaları gerekir. Bu nedenle pıhtılaşma durumunun izlenmesi, çözünen intravasküler pıhtıların yönetimi ve tedavisinde önemli bir rol oynar. Pıhtı oluşumu, gücü ve lizis dinamiklerini ölçen ve pıhtı tutarlılığı hakkında bilgi sağlayan tromboelastografi (TEG), pıhtılaşma durumunu ve trombolitik tedaviye yanıtı değerlendirmede yararlı bir araç olarak kabul edilmiştir. Kedilerde intravenöz tPA ile uygulanan trombolitik tedavinin tromboelastografik takibini gösteren bir çalışma bulunmamaktadır. Bu nedenle burada hipertrofik kardiyomiyopatiye (HCM) bağlı ATE'li bir kedide tPA kullanılarak başarılı bir trombolizi rapor ettik ve ilk kez TEG ile trombolitik tedaviyi izledik.

🔖

Cite This Article

KOCATÜRK, M., LEVENT, P., YILMAZ, Z. (2023). Thromboelastography evaluation of tissue plasminogen activator therapy in a cat with acute aortic thromboembolism due to hypertrophic cardiomyopathy. Türk Veteriner Cerrahi Dergisi, Cilt: 2 Sayı: 1, 10–16. https://ajindex.com/articles/970285

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Payne J., Borgeat K., Brodbelt D.C., Connolly D.J., Luis Fuentes V.: Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. J. Vet. Cardiol. 2015, (17): 318-328
  2. Whelan M., O’Toole T.: The use of thrombolytic agents. Compendium. 2007; 29: 28
  3. Niedermeyer J., Meissner E., Fabel H.: Thrombolytic therapy in pulmonary embolism. Indications and therapeutic strategies. Z. Gesamte Inn. Med. 1993, 48(6-7): 332-43
  4. Heiferman D.M., Li D.D., Pecoraro N.C., Smolenski A.M., Tsimpas A., Ashley W.W.: Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2017, 26(12): 3004-3008
  5. Borgeat K., Wright J., Garrod O., Payne J.R., Fuentes V.L.: Arterial Thromboembolism in 250 Cats in General Practice: 2004–2012. J. Vet. Intern. Med. 2014; 28(1): 102-108
  6. Fuentes V.L.: Arterial Thromboembolism: Risks, realities and a rational first-line approach. J. Feline Med. Surg. 2012, 14 (7): 459-470
  7. Fuentes V.L., Abbott J., Chetboul V., Côté E., Fox P.R., Häggström J., Kittleson M.D., Schober K., Stern J.A.: ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J. Vet. Intern. Med. 2020, 1-16
  8. Martin U., Sponer G., Strein K.: Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J. Am. Coll. Cardiol. 1992, 19(2): 433-40
  9. Diaz D.M., Scansen B.A., Lake Z., Shropshire S., Orton E.C., Guillaumin J.: Clinical use of tissue plasminogen activator for systemic thrombolysis in dogs and cats. J. Vet. Cardiol. 2022, 41: 154-164
  10. Sutton B., Long Mays E., McLaughlin C.: Case Report: Successful Reperfusion of Pulmonary Thromboembolism Using tPA in a Cat. Front. Vet. Sci. 2022, 20(9): 851106
  11. Moore K., Morris N., Dhupa N., Murtaugh R., Rush J.: Retrospective Study of Streptokinase Administration in 46 Cats with Arterial Thromboembolism. J. Vet. Emerg. Crit. Care. 2000, 10: 245-257
  12. White H.D.: Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction. Chest. 1989, 95(5 Suppl): 265S-269S
  13. Gravanis I., Tsirka S.E.: Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin. Ther. Targets. 2008, 12(2): 159-70.